Skip to main content
NewslettersWatchlist

Cardiol Therapeutics Inc(CRDL-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.58
Day High2.73
Open:2.73
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
Newsfile
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
Newsfile
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
Newsfile
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
Newsfile
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Newsfile
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Baystreet
Stocks in play: Cardiol Therapeutics Inc
Newsfile
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024
AI-generated - The Globe and Mail
Cardiol Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CRDL)
AI-generated - The Globe and Mail
Cardiol Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CRDL)
Newsfile
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
Newsfile
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
TheNewswire.com
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Newsfile
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
TheNewswire.com
Sector Spotlight: Orphan Drug Developers With Significant Upside
The Globe and Mail
Thursday’s analyst upgrades and downgrades
AI-generated - The Globe and Mail
Cardiol Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CRDL)
Newsfile
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Baystreet
Manufacturing, Housing Due Next Week in Canada
Newsfile
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
AI-generated - The Globe and Mail
Cardiol Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CRDL)

Profile

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.